178 related articles for article (PubMed ID: 23284167)
1. Small molecule targeting Cdc42-intersectin interaction disrupts Golgi organization and suppresses cell motility.
Friesland A; Zhao Y; Chen YH; Wang L; Zhou H; Lu Q
Proc Natl Acad Sci U S A; 2013 Jan; 110(4):1261-6. PubMed ID: 23284167
[TBL] [Abstract][Full Text] [Related]
2. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor.
Gao Y; Dickerson JB; Guo F; Zheng J; Zheng Y
Proc Natl Acad Sci U S A; 2004 May; 101(20):7618-23. PubMed ID: 15128949
[TBL] [Abstract][Full Text] [Related]
3. mDia1 and Cdc42 Regulate Activin B-Induced Migration of Bone Marrow-Derived Mesenchymal Stromal Cells.
Wang X; Tang P; Guo F; Zhang M; Yan Y; Huang M; Chen Y; Zhang L; Zhang L
Stem Cells; 2019 Jan; 37(1):150-162. PubMed ID: 30358011
[TBL] [Abstract][Full Text] [Related]
4. Targeting Rac and Cdc42 GTPases in Cancer.
Maldonado MDM; Dharmawardhane S
Cancer Res; 2018 Jun; 78(12):3101-3111. PubMed ID: 29858187
[TBL] [Abstract][Full Text] [Related]
5. Intersectin (ITSN) family of scaffolds function as molecular hubs in protein interaction networks.
Wong KA; Wilson J; Russo A; Wang L; Okur MN; Wang X; Martin NP; Scappini E; Carnegie GK; O'Bryan JP
PLoS One; 2012; 7(4):e36023. PubMed ID: 22558309
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a Cdc42 protein inhibitor and its use as a molecular probe.
Hong L; Kenney SR; Phillips GK; Simpson D; Schroeder CE; Nöth J; Romero E; Swanson S; Waller A; Strouse JJ; Carter M; Chigaev A; Ursu O; Oprea T; Hjelle B; Golden JE; Aubé J; Hudson LG; Buranda T; Sklar LA; Wandinger-Ness A
J Biol Chem; 2013 Mar; 288(12):8531-8543. PubMed ID: 23382385
[TBL] [Abstract][Full Text] [Related]
7. A Rac1/Cdc42 GTPase-specific small molecule inhibitor suppresses growth of primary human prostate cancer xenografts and prolongs survival in mice.
Zins K; Lucas T; Reichl P; Abraham D; Aharinejad S
PLoS One; 2013; 8(9):e74924. PubMed ID: 24040362
[TBL] [Abstract][Full Text] [Related]
8. Emerging roles for intersectin (ITSN) in regulating signaling and disease pathways.
Hunter MP; Russo A; O'Bryan JP
Int J Mol Sci; 2013 Apr; 14(4):7829-52. PubMed ID: 23574942
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the small GTPase Cdc42 in regulation of epileptic-seizure in rats.
Zhang Y; Liu J; Luan G; Wang X
Neuroscience; 2015 Mar; 289():381-91. PubMed ID: 25595978
[TBL] [Abstract][Full Text] [Related]
10. Vav family exchange factors: an integrated regulatory and functional view.
Bustelo XR
Small GTPases; 2014; 5(2):9. PubMed ID: 25483299
[TBL] [Abstract][Full Text] [Related]
11. Cdc42 inhibitor ML141 enhances G-CSF-induced hematopoietic stem and progenitor cell mobilization.
Chen C; Song X; Ma S; Wang X; Xu J; Zhang H; Wu Q; Zhao K; Cao J; Qiao J; Sun X; Li D; Zeng L; Li Z; Xu K
Int J Hematol; 2015 Jan; 101(1):5-12. PubMed ID: 25315193
[TBL] [Abstract][Full Text] [Related]
12. Spatial control of Cdc42 signalling by a GM130-RasGRF complex regulates polarity and tumorigenesis.
Baschieri F; Confalonieri S; Bertalot G; Di Fiore PP; Dietmaier W; Leist M; Crespo P; Macara IG; Farhan H
Nat Commun; 2014 Sep; 5():4839. PubMed ID: 25208761
[TBL] [Abstract][Full Text] [Related]
13. Targeting Cdc42 with the small molecule drug AZA197 suppresses primary colon cancer growth and prolongs survival in a preclinical mouse xenograft model by downregulation of PAK1 activity.
Zins K; Gunawardhana S; Lucas T; Abraham D; Aharinejad S
J Transl Med; 2013 Nov; 11():295. PubMed ID: 24279335
[TBL] [Abstract][Full Text] [Related]
14. Adaptor proteins intersectin 1 and 2 bind similar proline-rich ligands but are differentially recognized by SH2 domain-containing proteins.
Novokhatska O; Dergai M; Tsyba L; Skrypkina I; Filonenko V; Moreau J; Rynditch A
PLoS One; 2013; 8(7):e70546. PubMed ID: 23936226
[TBL] [Abstract][Full Text] [Related]
15. Fast neurotransmitter release regulated by the endocytic scaffold intersectin.
Sakaba T; Kononenko NL; Bacetic J; Pechstein A; Schmoranzer J; Yao L; Barth H; Shupliakov O; Kobler O; Aktories K; Haucke V
Proc Natl Acad Sci U S A; 2013 May; 110(20):8266-71. PubMed ID: 23633571
[TBL] [Abstract][Full Text] [Related]
16. Targeting Cdc42 in cancer.
Arias-Romero LE; Chernoff J
Expert Opin Ther Targets; 2013 Nov; 17(11):1263-73. PubMed ID: 23957315
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Cdc42-intersectin interaction by small molecule ZCL367 impedes cancer cell cycle progression, proliferation, migration, and tumor growth.
Aguilar BJ; Zhao Y; Zhou H; Huo S; Chen YH; Lu Q
Cancer Biol Ther; 2019; 20(6):740-749. PubMed ID: 30849276
[TBL] [Abstract][Full Text] [Related]
18. MYBL1 induces transcriptional activation of ANGPT2 to promote tumor angiogenesis and confer sorafenib resistance in human hepatocellular carcinoma.
Zhu J; Wu Y; Yu Y; Li Y; Shen J; Zhang R
Cell Death Dis; 2022 Aug; 13(8):727. PubMed ID: 35987690
[TBL] [Abstract][Full Text] [Related]
19. RPEL-family rhoGAPs link Rac/Cdc42 GTP loading to G-actin availability.
Diring J; Mouilleron S; McDonald NQ; Treisman R
Nat Cell Biol; 2019 Jul; 21(7):845-855. PubMed ID: 31209295
[TBL] [Abstract][Full Text] [Related]
20. A Natural Small Molecule Mitigates Kidney Fibrosis by Targeting Cdc42-mediated GSK-3β/β-catenin Signaling.
Hu X; Gan L; Tang Z; Lin R; Liang Z; Li F; Zhu C; Han X; Zheng R; Shen J; Yu J; Luo N; Peng W; Tan J; Li X; Fan J; Wen Q; Wang X; Li J; Zheng X; Liu Q; Guo J; Shi GP; Mao H; Chen W; Yin S; Zhou Y
Adv Sci (Weinh); 2024 Apr; 11(13):e2307850. PubMed ID: 38240457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
